MedinCell appointed Sabri Markabi as Board of Directors. Sabri Markabi, brings with him many years of experience in the field of pharmaceutical development and R&D. With this nomination, MedinCell is strengthening its Supervisory Board at a time when the first treatment using BEPO is currently undergoing clinical testing in the United States and several other long-acting treatments are already in development.